Status:
COMPLETED
Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)
Lead Sponsor:
AstraZeneca
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
60+ years
Phase:
PHASE1
Brief Summary
A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML). The first three patients to complete a...
Eligibility Criteria
Inclusion
- Newly diagnosed patient.
- Provision of written informed consent.
- De Novo (primary) or Secondary AML.
- Not eligible for intensive induction chemotherapy because of medical, social or psychological reasons.
Exclusion
- Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL).
- Patients with blast crisis of chronic myeloid leukaemia.
- Persistent, chronic, clinically significant toxicities from any prior anti- cancer therapy greater than CTCAE Grade 1 (except alopecia).
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00926731
Start Date
June 1 2009
End Date
May 1 2011
Last Update
June 16 2011
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Cleveland, Ohio, United States
2
Research Site
Houston, Texas, United States
3
Research Site
Le Chesnay, France
4
Research Site
Villejuif, France